In this study we focus on the NRF2-AKR1C1/2 pathway to further characterize the molecular basis of chemoresistance and propose as therapy option in recurrent ovarian cancer carboplatin in combination with the synthetic progesterone MPA. This evidence concerns the gene AKR1C1 and ovarian cancer.